Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials.

Deng B, Ruan T, Lu W, Ying J, Li S, Zhou R, Mu D

Endocrine13 May 2024Cited by 6 (Europe PMC)

PMID38740695DOI10.1007/s12020-024-03857-6PepBankPUB-38740695

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Mazdutide.

01HumanNot a test of Mazdutide aloneSystematic reviewEfficacy outcome
In a meta-analysis of placebo-controlled trials of mazdutide and cotadutide, the dual agonists reduced HbA1c versus placebo (mean difference -0.63%).
In plain wordsIn a pooled analysis of mazdutide and cotadutide trials, HbA1c fell more than with placebo.
Peptide
Mazdutide
Outcome
DecreaseHbA1c change (pooled)
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
Mean difference HbA1c
−0.63%
pooled mazdutide and cotadutide vs placebo
Source sentences
Summary
HbA1c (MD = -0.63%; 95% CI = [-0.82, -0.44]; P < 0.00001)
1 context sentence(design, population, supporting numbers)
Summary · context
This study aimed to investigate the effects of randomized, placebo-controlled trials involving the GLP-1 and glucagon receptor dual agonists, mazdutide, and cotadutide, on glycaemic control and body weight changes in individuals with type 2 diabetes mellitus (T2DM), obesity, or both.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-3874069501
02HumanNot a test of Mazdutide aloneSystematic reviewEfficacy outcome
In a meta-analysis of placebo-controlled trials of mazdutide and cotadutide, the dual agonists reduced body weight versus placebo (mean difference -4.16%).
In plain wordsIn a pooled analysis of mazdutide and cotadutide trials, body weight fell more than with placebo.
Peptide
Mazdutide
Outcome
DecreaseBody weight percentage change (pooled)
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference body weight change
−4.16%
pooled mazdutide and cotadutide vs placebo
Source sentences
Summary
percentage change in body weight (MD = -4.16%; 95% CI = [-5.41, -2.92]; P < 0.00001).
1 context sentence(design, population, supporting numbers)
Summary · context
This study aimed to investigate the effects of randomized, placebo-controlled trials involving the GLP-1 and glucagon receptor dual agonists, mazdutide, and cotadutide, on glycaemic control and body weight changes in individuals with type 2 diabetes mellitus (T2DM), obesity, or both.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-3874069503
03HumanNot a test of Mazdutide aloneSystematic reviewEfficacy outcome
In a meta-analysis of placebo-controlled trials of mazdutide and cotadutide, the dual agonists reduced fasting plasma glucose versus placebo (mean difference -1.71 mmol/L).
In plain wordsIn a pooled analysis of mazdutide and cotadutide trials, fasting blood glucose fell more than with placebo.
Peptide
Mazdutide
Outcome
DecreaseFasting plasma glucose change (pooled)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
Mean difference fasting plasma glucose
−1.71 mmol/L
pooled mazdutide and cotadutide vs placebo
Source sentences
Summary
fasting plasma glucose (MD = -1.71 mmol/L; 95% CI = [-2.31, -1.10]; P < 0.00001)
1 context sentence(design, population, supporting numbers)
Summary · context
This study aimed to investigate the effects of randomized, placebo-controlled trials involving the GLP-1 and glucagon receptor dual agonists, mazdutide, and cotadutide, on glycaemic control and body weight changes in individuals with type 2 diabetes mellitus (T2DM), obesity, or both.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-3874069502
04HumanNot a test of Mazdutide aloneSystematic reviewSafety outcome
In a meta-analysis of mazdutide and cotadutide trials, serious adverse events did not differ significantly from placebo (OR 1.03).
In plain wordsIn a pooled analysis of mazdutide and cotadutide trials, serious side effects were not significantly more common than with placebo.
Peptide
Mazdutide
Outcome
No significant changeSerious adverse events (pooled)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Measurements
Odds ratio serious adverse events
1.03 OR
pooled mazdutide and cotadutide vs placebo
Source sentences
Summary
no significant change in serious adverse events (OR = 1.03; 95% CI = [0.61, 1.75]; P = 0.91)
1 context sentence(design, population, supporting numbers)
Summary · context
This study aimed to investigate the effects of randomized, placebo-controlled trials involving the GLP-1 and glucagon receptor dual agonists, mazdutide, and cotadutide, on glycaemic control and body weight changes in individuals with type 2 diabetes mellitus (T2DM), obesity, or both.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-3874069504
05HumanNot a test of Mazdutide aloneSystematic reviewSafety outcome
In a meta-analysis of mazdutide and cotadutide trials, the odds of treatment-emergent adverse events were higher than with placebo (OR 2.52).
In plain wordsIn a pooled analysis of mazdutide and cotadutide trials, side effects during treatment were more likely than with placebo.
Peptide
Mazdutide
Outcome
IncreaseTreatment-emergent adverse events (pooled)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Measurements
Odds ratio treatment-emergent adverse events
2.52 OR
pooled mazdutide and cotadutide vs placebo
Source sentences
Summary
significantly higher odds of treatment-emergent adverse events (OR = 2.52; 95% CI = [1.92, 3.30]; P < 0.00001)
1 context sentence(design, population, supporting numbers)
Summary · context
This study aimed to investigate the effects of randomized, placebo-controlled trials involving the GLP-1 and glucagon receptor dual agonists, mazdutide, and cotadutide, on glycaemic control and body weight changes in individuals with type 2 diabetes mellitus (T2DM), obesity, or both.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-3874069505
06HumanNot a test of Mazdutide aloneSystematic reviewSafety outcome
In a meta-analysis of mazdutide and cotadutide trials, the odds of vomiting were higher than with placebo (OR 6.05).
In plain wordsIn a pooled analysis of mazdutide and cotadutide trials, vomiting was more likely than with placebo.
Peptide
Mazdutide
Outcome
IncreaseVomiting (pooled)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Odds ratio vomiting
6.05 OR
pooled mazdutide and cotadutide vs placebo
Source sentences
Summary
vomiting (OR = 6.05; 95% CI = [3.52, 10.40]; P < 0.00001).
1 context sentence(design, population, supporting numbers)
Summary · context
This study aimed to investigate the effects of randomized, placebo-controlled trials involving the GLP-1 and glucagon receptor dual agonists, mazdutide, and cotadutide, on glycaemic control and body weight changes in individuals with type 2 diabetes mellitus (T2DM), obesity, or both.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Report a problemFND-3874069506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.